Article
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Breast cancer research and treatment - 1 May 2013
Ramirez-Ardila Diana E, Helmijr Jean C, Look Maxime P, Lurkin Irene, Ruigrok-Ritstier Kirsten, van Laere Steven, Dirix Luc, Sweep Fred C, Span Paul N, Linn Sabine C, Foekens John A, Sleijfer Stefan, Berns Els M J J, Jansen Maurice P H M
Abstract excerpt
PIK3CA mutations occur frequently in breast cancer, predominantly in exons 9 and 20. The aim of this retrospective study is to evaluate the PIK3CA mutation status for its relationship with prognosis and first-line endocrine therapy outcome. PIK3CA exon 9 and 20 were evaluated for mutations in 1,352 primary breast cancer specimens by SnaPshot multiplex analyses. The mutation status was studied for their...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.